Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.

#42

Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.

Aim(s): To compare the outcome of two chemotherapy regimens for the treatment of progressive, undifferentiated neuroendocrine carcinomas.

Materials and methods: Eighteen patients (11 males; age 56.7±2.5) with proven progressive disease were enrolled (mean Ki-67 33.6±4.8%). Patients were treated as follows: from 2005 to 2007 with regimen A (carboplatin, paclitaxel, etoposide)1; and from 2007 to 2009 with regimen B (cisplatin, etoposide)2. This change was due to low tolerability of regimen A. The standard procedure used for imaging-based evaluation was computed tomography, which was performed every three months. After chemotherapy, patients were followed up until progression.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Deutschbein T, Unger N, Yuece A, Lahner H, Mann K,

Keywords: efficacy, cytotoxic agents, ,